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ABSTRACT
Objectives: Approximately 10% (40 000) of US
quitline enrollees who smoke cigarettes report current
use of electronic nicotine delivery systems (ENDS);
however, little is known about callers’ ENDS use. Our
aim was to describe why and how quitline callers use
ENDS, their beliefs about ENDS and the impact of
ENDS use on callers’ quit processes and use of FDA-
approved cessation medications.
Design: Qualitative interviews conducted 1-month
postregistration. Interviews were recorded, transcribed,
double-coded and analysed to identify themes.
Setting: Oklahoma Tobacco Helpline.
Participants: 40 callers aged ≥18 who were seeking
help to quit smoking were using ENDS at registration
and completed ≥1 programme calls.
Results: At 1-month postregistration interview, 80%
of callers had smoked cigarettes in the last 7 days,
almost two-thirds were using ENDS, and half were
using cessation medications. Nearly all believed ENDS
helped them quit or cut down on smoking; however,
participants were split on whether they would
recommend cessation medications, ENDS or both
together for quitting. Confusion and misinformation
about potential harms of ENDS and cessation
medications were reported. Participants reported using
ENDS in potentially adaptive ways (eg, using ENDS to
cut down and nicotine replacement therapy to quit, and
stepping down nicotine in ENDS to wean off ENDS
after quitting) and maladaptive ways (eg, frequent
automatic ENDS use, using ENDS in situations they did
not previously smoke, cutting down on smoking using
ENDS without a schedule or plan to quit), which could
impact the likelihood of quitting smoking or continuing
ENDS use.
Conclusions: These qualitative findings suggest
quitline callers who use ENDS experience confusion
and misinformation about ENDS and FDA-approved
cessation medications. Callers also use ENDS
in ways that may not facilitate quitting smoking.
Opportunities exist for quitlines to educate ENDS
users and help them create a coordinated plan most
likely to result in completely quitting combustible
tobacco.
INTRODUCTION
Use of electronic nicotine delivery systems
(ENDS), including electronic cigarettes
(e-cigarettes), has increased considerably in
recent years, particularly among current and
former cigarette smokers.1 2 In 2014, 47.6%
of current cigarette smokers and 55.4% of
recent former cigarette smokers had ever
tried an e-cigarette.3 ENDS use among
current smokers who call state quitlines is also
common; state quitlines are free, typically
phone-based tobacco cessation programmes
available in all 50 states in the USA.4 In 2012,
approximately one-third of quitline enrollees
reported ever using ENDS,5 and from 2013 to
2015, ∼10% reported current use at registra-
tion.6 An estimated half of these individuals
reported using ENDS to try to quit smoking
cigarettes.5 6
Although ENDS may be commonly used by
adults as a smoking cessation aid, they have
not been approved by the US Food and
Strengths and limitations of this study
▪ Dual users of cigarettes and electronic nicotine
delivery system (ENDS) who were in the middle
of an attempt to quit smoking were interviewed
at 1-month postquitline registration, which
allowed for timely reporting of quitting strategies
and experiences using ENDS and cessation
medications.
▪ In-depth qualitative interviews were completed
with 40 dual users of cigarettes and ENDS to
obtain detailed reports of experiences from a
range of ENDS users.
▪ Interviews were recorded, transcribed and
double coded to increase the trustworthiness of
extracted themes.
▪ Findings from this small sample of Oklahoma
Tobacco Helpline enrollees may not generalise to
all ENDS users.
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Drug Administration (FDA) for this purpose. To date,
there is no conclusive scientiﬁc evidence that ENDS are
effective for long-term cessation from conventional
cigarettes,7–11 and the long-term health impacts of
ENDS use among adults are uncertain.8 12 13 In light of
this uncertainty, health professionals and treatment pro-
viders are seeking to identify the best way to help
smokers who are using ENDS during their smoking ces-
sation process. However, limited information is available
about quitline callers’ experiences using ENDS and
their knowledge and beliefs about the products. This
information is critical to help quitlines determine how
best to address ENDS use given that an estimated 40 000
ENDS users call quitlines each year for help quitting
traditional tobacco products.4 6
Few studies have assessed factors related to ENDS use
among US quitline callers. Accordingly, this study
employed qualitative methods to assess quitline callers’
opinions about and experiences using ENDS, including
their beliefs about ENDS and smoking cessation, in-
teractions with quitline counsellors about ENDS and
perceptions of ENDS versus FDA-approved medications,
including nicotine replacement therapy (NRT).
METHODS
Participants
Prenotiﬁcation letters were mailed to 65 randomly
selected participants who met study eligibility criteria
∼3 weeks after Oklahoma Tobacco Helpline registration.
Letters included a study overview and stated that study
staff would be in contact about the study. Nineteen
could not be reached after multiple attempts and six
refused participation. Forty state quitline callers who
wanted to quit smoking and called the Oklahoma
Tobacco Helpline between November 2014 and
February 2015 completed the interview. A minimum
sample size target of 40 was selected to ensure inclusion
of diverse ENDS users with regard to reasons for ENDS
use. The interview team agreed that saturation was
reached after 40 participants.
Participants were reached via phone, provided
informed consent and completed an interview
∼1 month after registration with the Helpline. Callers
were eligible for the study if, at the time of registration,
they (1) currently smoked conventional cigarettes; (2)
were currently using ENDS as assessed by a standard
quitline question (“Do you currently use electronic
cigarettes, e-cigarettes or vapour cigarettes?”); (3) spoke
English; (4) requested a Helpline intervention; (5) were
18 or older; (6) completed at least one call with a quit
coach lasting at least 5 min and (7) provided consent for
follow-up contact. Pregnant callers were excluded. Four
participants used another form of tobacco product (eg,
pipe, smokeless tobacco) in addition to cigarettes and
ENDS at the time of registration. A US$49 gift card to
Amazon or Walmart was provided to participants who
completed the interview. All study procedures were
approved by the University of Oklahoma Institutional
Review Board.
The Helpline programme
All participants were enrolled in a one-call or ﬁve-call
phone-based cessation programme, which also included
a 2-week or 8-week supply of NRT, a printed quit guide
and access to an interactive online cessation resource.14
Intensity of Helpline service is determined by insurance
status: Callers with no insurance are eligible for the
ﬁve-call programme and 8-weeks of NRT, while callers
with Medicaid also receive the ﬁve-call programme but
only 2-weeks of NRT from the Helpline. Callers with
private insurance are eligible for the single-call pro-
gramme and 2 weeks of NRT. Coaching calls focus on
developing a quit plan, building skills for coping with
cravings and triggers, enlisting social support and using
FDA-approved cessation medications.15 16
With regard to using ENDS to quit smoking, Helpline
Quit Coaches were trained to not promote the use of
ENDS for quitting tobacco and to provide education
that there is not empirical evidence proving ENDS are
safe and effective cessation tools. Smokers interested in
switching to ENDS would not be discouraged from
doing so and would be educated that the safety of long-
term use of ENDS is unclear.17
Interviews
Interviews were conducted over the phone in private
ofﬁces by two female graduate research assistants at the
University of Oklahoma College of Public Health.
Interviewers were enrolled in graduate training in epi-
demiology, had received extensive training in research
methods, had interviewing experience from previous
studies and received training in qualitative interviewing
techniques. Interviewers followed a semistructured inter-
view guide and were encouraged to ask additional
probing questions. Topics discussed in the interviews
were selected to investigate current gaps in knowledge
about how ENDS were perceived and used by quitline
callers. Topics included reasons for ENDS use, current
ENDS and tobacco use, Helpline experience, experience
with FDA-approved cessation medications, ENDS use
details and intentions to quit. Interviews lasted 35.2 min
on average (range: 22.1–61.5 min), were audio recorded
and transcribed verbatim. A series of questions request-
ing feedback about the interview were also asked of the
ﬁrst eight participants.
Coding and analysis
Template analysis was used to guide the coding
process.18 A preliminary codebook was developed after
reading ﬁve transcripts. The codebook focused on topics
queried during the interview and themes that arose in
participants’ responses. Themes were then further orga-
nised into larger concepts (eg, if initially separated
topics yielded similar themes and were best grouped
together), while grounding all identiﬁed themes in
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participant’s words. Four individuals coded the inter-
views. Each interview was double-coded. Double-coding
was reviewed, and consensus was reached for each inter-
view. For analyses of coded data, our primary aim was to
describe themes present in the data. We used a constant
comparative approach, repeatedly returning to the tran-
scripts and codes to ensure the accuracy and increase
the depth of our summary of themes and to extract
exemplary participant quotations.19 20 Analyses were
conducted in MAXQDA (software for qualitative data
analysis, 1989–2016, VERBI Software—Consult—
Sozialforschung GmbH, Berlin, Germany).
RESULTS
Participants
Respondents were an average of 45 years old, 65%
women, 73% white non-Hispanic, 68% high school
degree or less education and predominately low income
(65% <US$25 000 annual income) (table 1).
Participants ranged in number of quit attempts prior to
contacting the Helpline: for 6, their Helpline enrolment
was a ﬁrst quit attempt, 15 had one to two previous
attempts, 10 had three to four previous attempts and 9
had ﬁve or more previous attempts. Thirty-three partici-
pants enrolled in the ﬁve-call programme and seven
enrolled in a one-call programme. All received a 2-week
or 8-week supply of NRT from the quitline. Participants
completed 1.7 calls (SD=1.12) during the programme
on average.
At registration, 19 reported using ENDS every day,
with the remaining 21 participants reporting non-daily
ENDS use; 33 reported using a tank system style ENDS
(which is reﬁlled with e-liquid by the user) and 37 said
they were thinking about quitting ENDS in addition to
cigarettes. All but one of the daily ENDS users used tank
systems. About half reported they were primarily using
ENDS to quit smoking, 13 said they were cutting down
to quit smoking and 3 said they were only using ENDS
to reduce smoking.
Table 2 displays products participants were using at
the time of the qualitative interview. A total of 32 had
smoked cigarettes in the last 7 days, 25 were currently
using ENDS and 21 were currently using an FDA-approved
cessation aid. Twenty-nine of the participants were using
two or three sources of nicotine (ie, cigarettes, ENDS
and/or NRT).
Interview themes
How participants reported using ENDS and FDA-approved
cessation medications
Descriptions of ENDS use
Participants discussed using ENDS as a quitting aid, as a
bridge product when smoking was not allowed, and for
a recreational experience. Callers also described using
ENDS as a partial replacement for cigarettes—either as
part of a cut down to quit strategy or, as a small number
reported, using ENDS only for cutting down on cigar-
ettes (not for quitting completely).
When asked whether ENDS helped them to quit or
cut down on smoking, most participants believed ENDS
helped them cut down on or quit cigarettes, including
quitting completely (n=7), quitting temporarily (n=7)
and cutting down without quitting (n=21). For example,
one participant who quit temporarily and was using
ENDS during her current quit attempt described:
To begin with, it [ENDS] took the place of the cigarette
and I still got the nicotine…I totally didn’t smoke for like
4 months. At that point, if I picked one [a cigarette] up
Table 1 Demographics and tobacco use characteristics
for respondents as reported at registration (N=40)
N Per cent
Age, mean±(SD) 45.0 (14.1)
Gender, female 26 65.0
Education
Less than high school 11 27.5
High school degree/GED 16 40.0
Some college/trade school or college/
trade school degree
13 32.5
Race/ethnicity
White, non-Hispanic 29 72.5
Black or African-American,
non-Hispanic
5 12.5
American Indian or Alaskan Native,
non-Hispanic
5 12.5
Other race, non-Hispanic 1 2.5
Health insurance status
Uninsured 18 45.0
Medicaid 8 20.0
Commercial 8 20.0
Medicare 5 12.5
‘Does not know’ 1 2.5
Employment status, employed 19 47.5
Chronic condition,* one or more 21 52.5
Mental health condition,† one or more 25 62.5
TTFU
Within 5 min 17 42.5
6–30 min 14 35.0
More than 30 min 6 15.0
Missing 3 7.5
Cigarette use per day (cpd), mean±(SD) 16.1 (12.3)
Number of years used tobacco, 20+
years
28 70.0
Annual income
Less than US$10 000 per year 18 45.0
US$10 000–US$25 000 per year 8 20.0
More than US$25 000 per year 12 30.0
Missing 2 5.0
*Chronic conditions included asthma, COPD, CAD and diabetes
(type II).
†Mental health conditions included ADHD, anxiety disorder,
bipolar, depression, gambling addiction, PTSD, schizophrenia and
substance use disorder.
ADHD, attention deficit hyperactivity disorder; CAD, coronary
artery disease; COPD, chronic obstructive pulmonary disease;
PTSD, post-traumatic stress disorder; TTFU, time to first use of
tobacco.
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and tasted it, I didn’t like the way it tasted. I didn’t care
for the light headed effect you got from it that comes
with not smoking it. You don’t smoke, that’s the way a cig-
arette affects you…I have been [using cigarettes] for
about the last month. We had some medical issues come
up and a lot of stress and I just fell back into it, but [I’m]
moving away from it. I’m doing the vapor stick more
than the cigarettes…I have the patches, but I haven’t
started them.
Alternatively, one participant felt ENDS increased his
urge to smoke and caused him to smoke more, and a
small number reported that ENDS did not change their
smoking. The latter participants noted that ENDS did
not work for them because they were still smoking; one
explained that carrying and maintaining their ENDS
device were inconvenient.
When asked what they liked and what they did not like
about using ENDS, participants reported positive and
negative perceptions of ENDS use. However, overall,
nearly all reported that they were satisﬁed with their
ENDS device. Positive aspects of ENDS use included fea-
tures of the use experience (eg, convenience of taking a
puff quickly as desired vs lighting and ﬁnishing a cigar-
ette; smell; taste; ﬂavours), environmental factors (eg,
no secondhand or thirdhand smoke, ash trays or lighted
ﬁre; can use where cannot smoke; less distracting to use
while driving), positive health attributions or beliefs
about ENDS (eg, health beneﬁts such as breathing
easier and less coughing, perceiving ENDS are healthier
than cigarettes), beliefs that ENDS helped with quitting
or cutting down (eg, behavioural substitute, control crav-
ings, avoid weight gain), nicotine delivery and concen-
tration options (eg, receiving needed nicotine; can taper
nicotine or use no nicotine ENDS), cost of ENDS and
others’ reactions to ENDS use (others prefer ENDS, no
judgement of use).
Negative perceptions of ENDS use were also reported,
including features of the ENDS device (leaks, hard to
maintain, weight/size/look, battery, breaks), beliefs that
ENDS are harmful or potentially harmful to health, that
ENDS do not help in quitting smoking (not satisfying,
insufﬁcient nicotine, does not help all of the time,
increases urge to smoke), concerns about ENDS habit
(addictive, continues hand to mouth habit), cost of
ENDS (particularly to start) and the learning curve for
use (process to ﬁnd right device or learn to use, hard
transition from smoking). Over a third of participants
reported negative experiences or minor side effects, pri-
marily coughing or sore throat/burning in back of
throat. Individual participants reported headache, pain
in lungs, dry mouth, dehydration and concern that
ENDS worsened chronic obstructive pulmonary disease
symptoms.
Descriptions of FDA-approved cessation medication use
When asked about past experiences using FDA-approved
cessation medications, nearly all participants reported
positive or mixed experiences. One participant
described her positive experiences with cessation medi-
cations: “The patch is excellent because it takes the edge
off.” Other participants had mixed experiences. For
example, a participant explained, “Chantix worked for
me but sometimes [insurance] wouldn’t pay for it and I
can’t afford it…My system on the patch—it rejects it.”
Only three participants reported that cessation medica-
tions were not perceived as helpful. For example, one
participant described: “I have tried patches, the gum,
the lozenges, and everything else and nothing has
worked.” Over half of the participants reported experi-
encing a side effect or reaction to an FDA-approved ces-
sation medication, including bad dreams, skin reactions
(rash, itchiness, burning sensation), emotional changes,
upset stomach, sore or itchy throat, feeling jittery or
having an abnormal taste in the mouth.
Table 2 Current tobacco and ENDS use during
qualitative interview at 1-month postregistration (N=40)
N Per cent
Current ENDS use
Every day 10 25.0
Some days 15 37.0
Rarely 6 15.0
Not at all 9 22.5
Current tobacco use (not including ENDS)
Within the last 24 hours 28 70.0
Within the last 7 days, but more than
24 hours ago
4 10.0
Within the last month, but more than
7 days ago
5 12.5
Within the last 3 months, but more than
1 month ago
2 5.0
Have you used NRT or cessation medications since
registration 1 month ago?
Yes 28 70.0
No 12 30.0
Current use of NRT or cessation
medications*
Yes 21 52.5
No 19 47.5
Current dual use of products: cigarettes, ENDS and NRT
or cessation medications†
Cigarettes and ENDS 10 25.0
Cigarettes, ENDS and NRT/meds 9 22.5
Cigarettes and NRT/meds 6 15.0
Cigarettes only 7 17.5
ENDS and NRT/meds 4 10.0
ENDS only 2 5.0
NRT/meds only 2 5.0
*Participant reported currently using NRT or a cessation
medication, or if current use was unclear, participant discussed
recent use of NRT or cessation medication (ie, within the last
7 days).
†Definitions of current use: any cigarette use in the last 7 days,
current every day or some days ENDS use (excludes rarely and
not at all), and current NRT/meds use defined as described in the
above footnote.
ENDS, electronic nicotine delivery system; NRT, nicotine
replacement therapy.
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A quarter of participants reported they were not using
an FDA-approved cessation medication at the time of
their interview because their quit date was still in the
future and they were waiting to start NRT until their quit
date. Some participants shared beliefs that they should
not use patches and smoke; for example, “I put the
patch on and I still smoked some…I would think, ‘I’m
just gonna have to take this patch off because you aren’t
supposed to smoke and wear the patch,’ so I just took
[the patch] off.”
Preferences for ENDS versus FDA-approved cessation
medications for quitting smoking
Participants were split on preferred methods for quitting
smoking; similar numbers recommended an
FDA-approved cessation medication only, ENDS only
and using both at the same time. In addition, several
participants reported no preference between ENDS and
cessation medications. Several participants noted open-
ness to trying any options that might work for them:
“anyone [who] wants to quit smoking [should] try any
method there is, because no person works the same.”
Participants who recommended an FDA-approved ces-
sation medication explained that medications helped
with quitting or urges and had better nicotine delivery.
For example, one participant described: “When I put it
[patch] on, physically I don’t crave a cigarette…that
doesn’t happen with the e-cigarette.” Some participants
also noted concerns about ENDS as a reason for their
choice including believing ENDS are harmful or not
knowing enough about safety, concerns about the addic-
tiveness of ENDS or the hand to mouth habit, that using
ENDS is not completely quitting, and insufﬁcient nico-
tine delivery. One participant explained:
You’re swapping out one cloud of smoke for another
cloud of smoke [with ENDS]…You still have the habit of
putting something in your mouth. You still have the habit
of blowing something out of your mouth…What is the
difference? I mean there’s no evidence out there that
proves that’s [ENDS use] any better than actual smoking
cigarettes…If you’re gonna quit nicotine, quit nicotine
all together. If you’re trying to quit smoking, I guess you
probably need to hit up on that nicotine patch.
Participants who felt ENDS were more helpful for quit-
ting highlighted the importance of ENDS as a behav-
ioural substitute for the hand to mouth habit of
smoking. They felt ENDS provided a better transition
from smoking, believed ENDS helped avoid weight gain
during quitting, liked that they could use ENDS as
needed, liked the throat hit from ENDS and preferred
the option to step down on nicotine. For example, one
participant shared,
It [patch] was a lot harder because you have the patch
[and] there is [a] no smoking period…The hand to
mouth gesture is there, it’s integrated in your system I
think, if you smoke for a long time. So it would be a lot
harder to go from smoking a cigarette to having the
patch on your arm. That’s really hard to do. In my
thought process, vaping to quit will actually be a better
thing because there’s still that interaction between hand
to mouth versus food going hand to mouth.
Most of these participants noted side effects with
FDA-approved cessation medications or that cessation
medications did not work well for them in the past or
did not provide sufﬁcient nicotine. Finally, participants
who believed it was most helpful to use FDA-approved
cessation medications and ENDS together for quitting
provided several explanations. Some noted this
approach would be preferred especially for long-time
smokers, some felt ENDS helped them with quitting
more than cessation medications and some felt an
FDA-approved cessation medication helped them more
with quitting than the ENDS product. Some in this
group of participants recommended using patches and
then ENDS (with or without nicotine) as a stopgap for
relapse or when urges were high, noting that patches
alone were not enough.
Misinformation and confusion about relative harm of ENDS
and FDA-approved medication
Views on relative harm of products
Participants were asked to rank ENDS, NRT and cigar-
ettes from most to least harmful and explain their rank-
ings. Slightly more than half of the participants ranked
FDA-approved cessation medications as least harmful,
just less than half ranked ENDS as least harmful and a
few felt FDA-approved cessation medications and ENDS
were equally harmful. All ranked cigarettes as most
harmful. Some participants ranked FDA-approved cessa-
tion medications as more harmful than ENDS due to
their reactions to FDA-approved cessation medications.
For example, one participant explained, “I would put
[patches] in the rank close to the cigarette, [because
they] make your heart beat really fast.” Some participants
provided explanations for their ranking choices that
involved misinformation about ENDS, FDA-approved ces-
sation medications or nicotine, as described in the next
section. Several participants also expressed lack of conﬁ-
dence in their knowledge about the relative harm of pro-
ducts, for example, stating, “I would probably have to say
that I don’t know. I think the vapor’s more harmful.
I really do not know.”
Misinformation and confusion about ENDS
Participants reported several inaccurate beliefs about the
safety and constituents of ENDS. Some participants
expressed beliefs that ENDS and the aerosol ENDS
produce are completely safe. For example, one partici-
pant said, “There’s not any chemicals in [ENDS] like
there are in actual cigarettes,” and another stated, “It’s a
vapor, I mean, you’re not really hurting anybody. You
could smoke it inside the building.” One participant
reported believing she was not receiving any nicotine
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from ENDS; she explained, “[When] I use the e-
cigarette, I really don’t think I am getting the nicotine
or anything in my lungs because it evaporates. I think I
am just getting a taste of nicotine.”
Views on long-term ENDS use
When asked what they thought about long-term use of
ENDS, almost equal numbers were concerned, support-
ive and unsure. Some participants’ explanations
reﬂected confusion or misbeliefs about ENDS.
Participants who had concerns about long-term ENDS
use either believed that ENDS are harmful or detrimen-
tal to health or thought ENDS may have negative
impacts if used long-term, but often thought short-term
use was likely okay. Those who were unsure often saw
beneﬁts to ENDS use (not smoking, feeling healthier)
or had not personally experienced any negative impacts
of using ENDS, but either (1) expressed uncertainty
about long-term use due to unknown constituents of
ENDS, the potential impact of aerosol on lungs or using
an addictive product or (2) did not know what to think
about long-term use (ie, did not know because they had
not read or heard anything about it or believed there
are conﬂicting opinions on this subject). Participants
who said they were supportive of long-term use were
most likely to report inaccurate information about
ENDS, such as that ENDS and the aerosol it produces
are completely safe (ie, the aerosol is just water vapour)
or that there were no concerns as long as one used
ENDS products that did not contain nicotine. Some of
these participants also noted the relative beneﬁt of using
ENDS rather than cigarettes.
Misinformation about FDA-approved cessation medications
Some participants also made statements that reﬂected
concerns about the safety of NRT or how to use NRT.
For example, one participant stated, “The patch has def-
initely got tar in it.” Another participant who believed
the patch and ENDS were equally harmful explained,
“with the patch, the nicotine [is] being absorbed into
your skin—that is chemicals, so that is not good.” A
third participant who rated patches as more harmful
than ENDS shared, “I don’t really know how to explain
it…it’s just that I’m scared to use them [patches].”
Another participant ranked NRT as more harmful than
ENDS because of concerns about overdosing on NRT.
Concerns about nicotine
Some participants focused on the safety of nicotine
regardless of whether it was delivered from ENDS or
FDA-approved cessation medications. One participant
stated, “Nicotine in pure form causes Alzheimer’s.” Two
participants believed their 0 mg nicotine ENDS product
was the least harmful product, “because nicotine is bad
for you;” both participants were still smoking cigarettes
at the time of the interview. Several others were also
unsure whether ENDS or NRT are more harmful or
ranked NRT as more harmful because they viewed
nicotine dependence or use as the main concern.
Several ranked ENDS as less harmful than the nicotine
patch because they believed ENDS deliver less nicotine.
Strategies used for incorporating ENDS in smoking
cessation plans
Participants described how they used ENDS devices
during their smoking cessation process. We categorised
these behaviours into potentially adaptive and maladap-
tive quit behaviours. These categories were not mutually
exclusive; some participants reported behaviours that
may be less likely to harm their quit process or possibly
help with quitting (potentially adaptive) as well as beha-
viours that may be more likely to establish a separate
ENDS habit or were less likely to reduce smoking
(potentially maladaptive).
Potentially adaptive quit behaviours
On the basis of the participants’ descriptions for how
they incorporated ENDS into their smoking cessation
plan, we identiﬁed ﬁve examples of potentially adaptive
behaviours. Some participants were using ENDS only,
but decided to or planned to switch to using a patch
along with a no-nicotine ENDS: “I’m trying something
different now that I got my patches in. I’m going to use
patches for the nicotine. And then I’m going to ﬁll my
e-cig with the zero nicotine. That way I have the habit
still and I’m getting the nicotine, but I can cut back with
the patches.” Second, other participants used NRT, such
as the patch, and used ENDS with nicotine when crav-
ings were high to avoid picking up a cigarette. Third,
multiple participants discussed stepping down the milli-
grams of nicotine in their ENDS liquid to wean off nico-
tine. For example, one participant described, “It
[ENDS] took the place of the cigarette and I still got the
nicotine and you’re able to cut down the amount of
nicotine you get in the vapor. You can get it in a 24, 18,
12, 7, 2, or 0 [mg/ml nicotine concentration] and I just
stepped down.” Fourth, several participants used ENDS
to cut down and completely replace smoking cigarettes
and then switched to the patch to quit cigarettes and
ENDS. Finally, a small number of participants com-
pletely switched from cigarettes to ENDS or cut down
cigarettes by replacing with ENDS and eventually fully
replaced all cigarettes with ENDS.
Potentially maladaptive quit behaviours
Four types of potentially maladaptive behaviours for
incorporating ENDS into smoking cessation plans were
identiﬁed. First, more than half of the participants
reported using ENDS in situations where they did not or
could not smoke, most frequently at work, in their car, at
home or in stores. Second, a group of participants had
difﬁculty describing their ENDS use because it had
become a frequent, automatic behaviour. One partici-
pant explained, “I can’t even count to be honest with
you…I just go ‘oh look, I want this’ and I grab it. I have
a lanyard that’s around my neck all day long.” Third,
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several participants who were cutting down to quit,
described partially replacing cigarettes with ENDS, but
choosing to smoke a cigarette when they were stressed
or their cravings were high. Fourth, while some partici-
pants described a plan for reducing nicotine intake and
weaning off ENDS, others were cutting down to quit
without a plan or schedule.
What is the role of the quitline?
ENDS users were asked what they remembered from
their conversation with Quit Coaches about ENDS. Half
remembered some conversation with their Quit Coach
about ENDS. The top four messages participants
reported receiving from Quit Coaches were: concerns
about ENDS, much is unknown about ENDS, use
encouraged or ‘ENDS are okay’ and avoiding dual use
of ENDS and cigarettes. One participant described how
use was discouraged, “I told them I used vapors and they
informed me that there [were] no FDA regulations on it
and they suggested I didn’t use those at all.”
Conversations about ENDS with Quit Coaches had
varying impact for different participants. The aforemen-
tioned participant described that she felt the quitline
was “very much discouraging use…I blew it off…to each
their own on their opinions on vaping. I don’t see any-
thing wrong with vaping.” However, another participant
stated that her conversation with the Quit Coach
changed her view of ENDS, “He made a really, really
good point that they are not regulated and you don’t
know what is in it. He really put an idea in my head.”
Several participants reported action or belief changes
following their conversation with a coach.
Participants were also asked what other messages they
would like from the quitline about ENDS. The majority
had no response or did not know. Several requested
more information in general or about the safety of
ENDS. A few participants had hoped to hear that it was
a good idea to vape or that ENDS are helpful with quit-
ting. Another participant described that she assumed
she should stop using ENDS before starting NRT
because the quitline recommended “that you discon-
tinue all nicotine intake other than the lozenges and
the gum,” but an explicit conversation about guidance
on using ENDS and patches would have been helpful.
Overall, ∼three-quarters of the 40 participants said they
would recommend other ENDS users call the quitline.
DISCUSSION
Analysis of interviews with 40 quitline callers who were
using ENDS during an attempt to quit cigarette smoking
revealed themes that may be relevant to consider when
approaching treatment with dual users of cigarettes and
ENDS. ENDS products were used in multiple ways,
including as a cessation aid, a partial replacement for
smoking prior to quitting, a bridge product when unable
to smoke and an enjoyable experience. In contrast,
FDA-approved cessation medications were typically
discussed only in the context of cessation, highlighting
the added complexity of counselling smokers using
ENDS. This contrast likely contributes to NRT and ENDS
being used differently. For example, some participants
discussed waiting to use NRT until their quit date or
stopping NRT use if they relapsed to smoking; these
use ‘rules’ that were not discussed for ENDS. The major-
ity of participants had positive use experiences with
ENDS, as well as with some FDA-approved cessation
medications. However, participants were split on whether
FDA-approved cessation medications, ENDS or using
FDA-approved cessation medications and ENDS simultan-
eously worked best for them for quitting smoking.
In addition, some participants shared inaccurate
beliefs about ENDS, FDA-approved cessation medica-
tions and nicotine. Participants’ beliefs about the pro-
ducts, whether accurate or inaccurate, can likely impact
how and whether participants incorporate ENDS and
FDA-approved cessation medications into their quit
plan. Findings from these interviews suggested that state
quitline callers who use ENDS would beneﬁt from add-
itional education about ENDS, FDA-approved cessation
medications, nicotine and the relative harm of these
products. Speciﬁcally, quitlines and other health profes-
sionals have an opportunity to provide information
about ENDS and quitting that will maximise the likeli-
hood of helping individual smokers quit completely.
Information callers receive may also impact what infor-
mation they share with others about ENDS and their use
of ENDS around others, including children.
The effectiveness of ENDS use for promoting long-
term cessation from conventional cigarettes is uncer-
tain.7–11 However, many smokers report using ENDS to
help them quit smoking,5 6 21 and some former smokers
report successfully using ENDS to quit.22–28 On the basis
of principles of behaviour change, strategies were noted
by respondents in this study that may be less likely to
result in harm during a quit process (potentially adap-
tive behaviours), including using patches and ENDS
together similar to combination therapy, using ENDS to
cut down and FDA-approved cessation devices to quit
completely and fully replacing cigarettes with ENDS.
Potentially maladaptive behaviours of cutting down
using ENDS were also noted, including using ENDS in
places they did not previously smoke, using ENDS in a
frequent unplanned manner and cutting down to quit
without a plan or schedule. ENDS use in situations parti-
cipants did not previously smoke may serve to increase
nicotine dependence, undermine the impact of tobacco
free policies, expose others to secondhand aerosol and
establish dual use of ENDS and cigarettes. Smokers who
cut down to quit, but continue to smoke in high craving
situations, may not develop coping skills for stress or
cravings in difﬁcult situations and may experience the
remaining cigarettes they smoke as particularly reinfor-
cing. Finally, research has shown that cutting down to
quit without a plan or schedule is less likely to be effect-
ive.29 30 These ﬁndings suggest that treatment providers
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may ﬁnd it useful to identify and discuss maladaptive
behaviours during smoking cessation treatment. Future
research is also warranted to better understand how
ENDS and cessation medication are used together
during a quit attempt, as well as the effectiveness of
these strategies.
Previous studies suggest that ENDS experimentation
or use may help to motivate a quit attempt (MAXQDA,
software for qualitative data analysis, 1989–2016).10–22 24–32
It is possible that some smokers who try ENDS will have
a positive experience that may bolster their motivation
and intention to quit (eg, feeling healthier, managing
cravings, reducing cigarettes per day), which appeared
to be the case for some in this study. Although research
has shown that reducing cigarette consumption is not
sufﬁcient to fully reduce health risks of smoking,23 33 34
cigarette reduction may be a step towards quitting for
individuals who have been unable to stop abruptly.
Some research suggests that a cut-down-to-quit strategy
that is guided on a schedule may yield similar outcomes
as abrupt quitting;29 30 35 however, cutting down to quit
has been found to be less effective in real-world
samples.36 In the present study, it was uncertain how
aware participants were of the importance of completely
quitting combustible tobacco. Given the number using a
cut-down-to-quit strategy, this represents an important
area for future research. Additionally, varying reasons
and methods for using ENDS, varying experiences with
using ENDS while quitting smoking and changes in
ENDS use from registration to the 1 month interview
highlight that the concept of ‘dual use’ of ENDS and
cigarettes is not unidimensional. Future research is
important to examine how patterns of dual use change
over time, particularly during different phases of a
smoker’s quit process, taking into account current
reasons for use. For example, using ENDS to prevent
relapse with some brief smoking lapses may need to be
viewed differently than long-term use of ENDS to cut
down on smoking with no plans to quit smoking
completely.
This study is subject to at least ﬁve limitations. First,
the ﬁndings from this small sample may not generalise
to all ENDS users. Second, the sample may also include
more ENDS ‘treatment failures’ than in the general
population; if smokers had successfully quit using their
ENDS device, they could have been less likely to call the
quitline for assistance.7 Third, most callers had com-
pleted one quitline call, and some had a limited
memory of the call. Interviewing callers after they had
an opportunity to complete more calls could yield differ-
ent information. Fourth, it was not possible to fully
account for the type of ENDS device used, use topog-
raphy or proﬁciency/experience as a user. Given that
these characteristics can impact nicotine delivery,37 38
these factors may have inﬂuenced preferences for use of
ENDS versus FDA-approved cessation medications for
quitting smoking. Finally, it was unclear if timing of the
interviews (eg, New Year and holidays) may have led to
delayed quit dates, or if that was part of the quitting
process for individuals in this sample.
In conclusion, in this sample of 40 ENDS users who
contacted a state quitline for help quitting smoking,
some ENDS users had confusion or misinformation
about ENDS, FDA-approved cessation medications, nico-
tine and the relative harm of these products. ENDS were
being used in ways that were unlikely to help with quit-
ting smoking, as well as in ways that may potentially
facilitate quitting smoking. These ﬁndings suggest that
quitlines have a unique opportunity to educate a signiﬁ-
cant number of ENDS users and to help them create a
coordinated quit plan most likely to result in completely
quitting combustible tobacco. These ﬁndings also
suggest important avenues for future research. Strategies
for educating smokers about ENDS and, if necessary,
changing inaccurate beliefs about products warrant
development and testing. Additionally, future research
could examine whether the use of cut-down-to-quit strat-
egies and relapse experiences are different for indivi-
duals who use ENDS during their quit process. Finally,
for quitline callers who plan to use ENDS as part of
their quit attempt, research is warranted to determine
whether certain information about ENDS or behavioural
support from the quitline may improve callers’ success
with quitting smoking.
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